4957 clinical trials
1024 cell line models
50 approved drugs
Molecular Synopsis
Drugs and clinical candidates

50 drugs have received FDA approval for Leukemia:

  • Alemtuzumab
  • Arsenic Trioxide
  • Asparaginase Erwinia chrysanthemi
  • Bendamustine Hydrochloride
  • Blinatumomab

536 drugs have a clinical trial registered for Leukemia.

21881 compounds have been tested in Leukemia (15570 <= 500nM potency).

Sources: cancer.gov, clinicaltrials.gov, ChEMBL.

Clinical trials
There are 4957 clinical trials for Leukemia, 3473 of which have one or more drug interventions, 1484 with no drug intervention.
Cell line models

There are 1024 Cell Line Models for Leukemia.

Source: COSMIC
Cell line models

Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Leukemia:
  • Preleukemia
  • Leukemia, Prolymphocytic, B-Cell
  • Leukemia, Prolymphocytic
  • Leukemia, Myelomonocytic, Chronic
  • Leukemia
The following terms have been mapped from cancer.gov to Leukemia:
  • Acute promyelocytic leukemia (APL) in patients whose cancer has a certain type of chromosome mutation that affects the PML gene and RARA gene. It is used:In adults with newly diagnosed APL that is low risk
  • T-cell acute lymphoblastic leukemia
  • Chronic myelogenous leukemia that is refractory (does not respond to treatment)
  • Meningeal leukemia (leukemia that has spread to the meninges). It is given as intrathecal therapy
  • Acute myeloid leukemia (AML). It is used with cytarabine and daunorubicin hydrochloride in newly diagnosed adults whose cancer has a mutation in the FLT3 gene